Assignee
PROXIMAGEN LLC
US·11 granted patents·6 pending applications·20 citations·filing 2015–2022
Top patents by PatentIndex Score
17 records- 0190US10428066B2Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitorsPROXIMAGEN LLC·Filed 2018·Granted Oct 1, 2019·6 cites·25 claims
- 0288US10995091B2CXCR4 receptor antagonistsPROXIMAGEN LLC·Filed 2018·Granted May 4, 2021·3 cites·14 claims
- 0386US10968223B2Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitorsPROXIMAGEN LLC·Filed 2020·Granted Apr 6, 2021·1 cites·24 claims
- 0485US10590125B2CompoundsPROXIMAGEN LLC·Filed 2016·Granted Mar 17, 2020·3 cites·9 claims
- 0585US10155761B2CXCR4 receptor antagonistsPROXIMAGEN LLC·Filed 2017·Granted Dec 18, 2018·4 cites·16 claims
- 0684US11512082B2Substituted imidazo[4,5-c]pyridine compounds and compositions thereofPROXIMAGEN LLC·Filed 2020·Granted Nov 29, 2022·1 cites·20 claims
- 0782US2023110165A1Substituted Imidazo[4,5-c]pyridine Compounds and Compositions ThereofPROXIMAGEN LLC·Filed 2022·Application pending·0 cites
- 0880US10766897B2Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitorsPROXIMAGEN LLC·Filed 2019·Granted Sep 8, 2020·1 cites·27 claims
- 0972US2022348577A1CXCR4 Receptor AntagonistsPROXIMAGEN LLC·Filed 2021·Application pending·0 cites
- 1067US11530208B2Imidazo[4,5-C]pyridine derived SSAO inhibitorsPROXIMAGEN LLC·Filed 2015·Granted Dec 20, 2022·1 cites·16 claims
- 1162US11369616B2Drug combination and its use in therapyPROXIMAGEN LLC·Filed 2018·Granted Jun 28, 2022·0 cites·10 claims
- 1258US2021024518A1Therapeutic compound and use in therapyPROXIMAGEN LLC·Filed 2020·Application pending·0 cites
- 1352US10738044B2Therapeutic compound and use in therapyPROXIMAGEN LLC·Filed 2016·Granted Aug 11, 2020·0 cites·3 claims
- 1449US2023190728A1New therapeutic uses of compoundsPROXIMAGEN LLC·Filed 2021·Application pending·0 cites
- 1544US2020147059A1New therapeutic uses of enzyme inhibitorsPROXIMAGEN LLC·Filed 2018·Application pending·0 cites
- 1643US2020281937A1Usl-311 for use in the treatment of cancerPROXIMAGEN LLC·Filed 2018·Application pending·0 cites
- 1739US11311552B2Therapies for cancerPROXIMAGEN LLC·Filed 2016·Granted Apr 26, 2022·0 cites·7 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →